CD274 Matched Antibody Pair (214) (APMAB-214LY)

Verocq, C., Decaestecker, C., Rocq, L., De Clercq, S., Verrellen, A., Mekinda, Z., ... & D'haene, N. (2020). The daily practice reality of PD‑L1 (CD274) evaluation in non‑small cell lung cancer: A retrospective study. Oncology letters, 19(5), 3400-3410.

Riemann, D., Schütte, W., Turzer, S., Seliger, B., & Möller, M. (2020). High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. Cancers, 12(10), 2966.

Kim, J. Y., Lee, K. H., Kang, J., Borcoman, E., Saada-Bouzid, E., Kronbichler, A., ... & Gamerith, G. (2019). Hyperprogressive disease during anti-PD-1 (PDCD1)/PD-L1 (CD274) therapy: a systematic review and meta-analysis. Cancers, 11(11), 1699.

Fabrizio, F. P., Trombetta, D., Rossi, A., Sparaneo, A., Castellana, S., & Muscarella, L. A. (2018). Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Therapeutic advances in medical oncology, 10, 1758835918815598.

Huang, C. Y., Chiang, S. F., Ke, T. W., Chen, T. W., You, Y. S., Chen, W. T. L., & Chao, K. C. (2018). Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer. Scientific reports, 8(1), 1-10.

Clavé, S., Pijuan, L., Casadevall, D., Taus, Á., Gimeno, J., Hernández‐Llodrà, S., ... & Salido, M. (2018). CD 274 (PDL 1) and JAK 2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients. Histopathology, 72(2), 259-269.

Yang, L., Cai, Y., Zhang, D., Sun, J., Xu, C., Zhao, W., ... & Pan, C. (2018). miR-195/miR-497 regulate CD274 expression of immune regulatory ligands in triple-negative breast cancer. Journal of breast cancer, 21(4), 371-381.

Sun, J., Lian, M., Ma, H., Wang, R., Ma, Z., Wang, H., ... & Fang, J. (2018). Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell carcinoma. Molecular medicine reports, 17(3), 3859-3869.

Lee, S. J., Jun, S. Y., Lee, I. H., Kang, B. W., Park, S. Y., Kim, H. J., ... & Kim, J. G. (2018). CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. Journal of cancer research and clinical oncology, 144(6), 1005-1014.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-CD274 Recombinant Antibody (CF073)

Mouse Anti-CD274 Recombinant Antibody (CBXC-2555)

Mouse Anti-CD274 (AA 19-238) Monoclonal Antibody (CBFYR0333)

Mouse Anti-CD274 Recombinant Antibody (MIH3)

Mouse Anti-CD274 Recombinant Antibody (CBYY-C1294)

Rabbit Anti-CD274 Recombinant Antibody (IHC411)

Mouse Anti-CD274 Recombinant Antibody (CB21A)

Mouse Anti-CD274 (AA 19-238) Monoclonal Antibody (CBFYR0335)

Rabbit Anti-CD274 Monoclonal Antibody (CBFYR-0050)

Mouse Anti-CD274 Recombinant Antibody (CBFYC-1192)

Isotype control